STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: SUEWALLST

Rhea-AI Summary

{"summary":"","positive":[],"negative":[],"faq":[]}

News Market Reaction – RGNX

-3.20%

15 alerts

-3.20% News Effect

-8.0% Trough in 28 hr 46 min

-$15M Valuation Impact

$463M Market Cap

0.6x Rel. Volume

On the day this news was published, RGNX declined 3.20%, reflecting a moderate negative market reaction. Argus tracked a trough of -8.0% from its starting point during tracking. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $15M from the company's valuation, bringing the market cap to $463M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Share price drop: $2.40 Single-day decline: 17.8% Closing price: $11.01 +5 more

8 metrics

Share price drop $2.40 Decline when truth emerged on January 28, 2026

Single-day decline 17.8% RGNX share price drop on January 28, 2026

Closing price $11.01 RGNX close on January 28, 2026 after disclosure

Patients treated 8 patients RGX-111 tolerability described in May 3, 2023 earnings call

Lead plaintiff deadline April 14, 2026 Deadline to seek lead plaintiff status in RGNX securities action

Current price $9.38 Pre-article trading level vs prior regulatory/legal overhang

52-week high $16.19 Pre-article 52-week high for RGNX

52-week low $5.035 Pre-article 52-week low for RGNX

Market Reality Check

Price: $8.57 Vol: Volume 725,149 is 0.74x t...

normal vol

$8.57 Last Close

Volume Volume 725,149 is 0.74x the 20-day average of 985,064, suggesting no outsized trading reaction pre-release. normal

Technical Shares at 9.38 are trading below the 200-day MA of 10.58, reflecting a weak intermediate trend.

Peers on Argus

RGNX is down 5.25% while key biotech peers mostly show smaller mixed moves (e.g....

RGNX is down 5.25% while key biotech peers mostly show smaller mixed moves (e.g., ARCT -2.1%, REPL -3.42%, ATYR +0.55%). This points to company-specific pressure rather than a broad sector move.

Historical Context

5 past events · Latest: Mar 11 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 11	Clinical trial update	Positive	-5.3%	Positive interim Phase I/II RGX-202 data including functional gains and safety.
Mar 05	Litigation-focused news	Negative	-4.6%	Law-firm style communication highlighting investor losses tied to setbacks.
Mar 05	Earnings and pipeline	Negative	-4.6%	2025 results plus FDA holds on RGX-111/121 and a CRL for RGX-121.
Mar 04	Conference presentations	Positive	+5.2%	RGX-202 presentations at the 2026 MDA Clinical & Scientific Conference.
Mar 02	Investor conferences	Positive	+2.2%	Planned participation in multiple March healthcare investor conferences.

Pattern Detected

Recent news shows mostly aligned price reactions, including selling on regulatory/earnings setbacks and one notable selloff on positive clinical data.

Recent Company History

Over the past weeks, RGNX has faced a cluster of significant catalysts. A positive Phase I/II update for RGX-202 on Mar 11, 2026 coincided with a -5.25% move, suggesting profit-taking or risk concerns despite encouraging data. Earlier in March, earnings and separate lawsuit-related headlines on Mar 5, 2026 preceded declines of about -4.6% each. In contrast, March conference and presentation announcements on Mar 2–4, 2026 saw modest gains, indicating investors have recently rewarded non-controversial pipeline visibility while reacting negatively to risk-focused disclosures.

Regulatory & Risk Context

Active S-3 Shelf · $300,000,000

Shelf Active

Active S-3 Shelf Registration 2025-11-26

$300,000,000 registered capacity

The company has an effective S-3 shelf filed on Nov 26, 2025 that permits offerings of up to $300,000,000 in various securities over time. It has already been tapped at least once, as indicated by a 424B5 prospectus supplement dated Feb 12, 2026, highlighting an active capacity to raise additional capital.

Market Pulse Summary

This announcement centers on a securities class action targeting prior safety-related communications...

Analysis

This announcement centers on a securities class action targeting prior safety-related communications about RGX-111, tying them to a historical 17.8% one-day drop and close at $11.01. It reinforces existing legal and regulatory overhangs stemming from MPS programs. Investors may monitor future disclosures, outcomes of the litigation process, and any additional updates on RGX-111 safety concerns alongside capital-raising activity from the $300,000,000 shelf.

Key Terms

securities class action, gene therapy, mucopolysaccharidosis type i, cns biomarker, +4 more

8 terms

securities class action regulatory

"is named as an individual defendant in a securities class action alleging"

A securities class action is a lawsuit brought by a group of investors who claim they lost money because a company or its executives made false or misleading statements about financial performance, risks, or business prospects. Think of it as many people pooling forces to challenge misleading information; it matters to investors because these cases can lead to large settlements or judgments, hurt a company’s reputation, drain cash, and cause share prices to fall or become more volatile.

gene therapy medical

"including RGX-111, a gene therapy for severe Mucopolysaccharidosis Type I"

Gene therapy is a medical technique that involves altering or replacing faulty genes in a person's cells to treat or prevent disease. It is considered a promising area of innovation because it has the potential to provide long-term or even permanent solutions to genetic conditions. For investors, advancements in gene therapy can signal opportunities in biotech companies and emerging treatments with significant growth potential.

mucopolysaccharidosis type i medical

"RGX-111, a gene therapy for severe Mucopolysaccharidosis Type I (MPS I)."

A rare inherited disorder caused by a missing or faulty enzyme that normally breaks down long sugar chains, so these molecules build up like trash piling up inside cells and tissues. It leads to progressive damage in organs, bones and the nervous system; for investors, it matters because treatments, clinical trials or approvals for therapies can change a company’s revenue outlook and the value of related biotech or pharmaceutical stocks.

cns biomarker medical

"highlighting "encouraging CNS biomarker activity." These statements spanned"

A CNS biomarker is a measurable biological sign—such as a molecule in cerebrospinal fluid, blood, or a brain scan—that indicates the state or activity of the central nervous system (brain and spinal cord). For investors, these markers act like dashboard warning lights for neurological disease and drug response: they can speed up drug development, reduce clinical trial risk by showing whether a treatment is hitting its target, and influence regulatory decisions and valuation.

neoplasm medical

"safety risks, including the potential for CNS neoplasm, yet continued"

A neoplasm is an abnormal growth of tissue that forms a lump or mass; it can be harmless (benign) or harmful (malignant, i.e., cancer). Think of it like a weed in a garden—sometimes it stays small and causes no trouble, other times it spreads and damages surrounding tissue. For investors, neoplasms matter because they drive demand for diagnostics, drugs, and treatments, influence clinical trial outcomes and regulatory decisions, and affect healthcare costs and company valuations.

section 20(a) regulatory

"liable as a controlling person under Section 20(a) of the Securities"

Section 20(a) is a U.S. securities law rule that can make a person or entity that has the power to control a company legally responsible for securities law violations committed by that company or its officers. Think of it like holding the captain of a ship partly responsible for the crew’s mistakes: investors can seek damages from both the company and those who exercised control, which affects how risks and potential recoveries are assessed.

securities exchange act regulatory

"controlling person under Section 20(a) of the Securities Exchange Act."

A securities exchange act is a law that sets the rules for how public securities markets operate, requiring regular disclosure by traded companies, policing insider trading, and overseeing market intermediaries. Think of it as a rulebook and referee combined: it forces companies to share financial and material information and gives regulators tools to investigate and punish unfair behavior, which helps investors make informed decisions and reduces the chance of fraud or market manipulation.

lead plaintiff regulatory

"LEAD PLAINTIFF DEADLINE: April 14, 2026Submit your claim"

The lead plaintiff is the representative investor chosen to speak and act on behalf of a group of shareholders in a securities lawsuit. Think of them as the elected spokesperson for a neighborhood when everyone sues a landlord: they coordinate the legal case, make strategic decisions, and negotiate settlements, so their choices can shape outcomes and any recovery that reaches all affected investors. Investors care because the lead plaintiff’s resources and approach can influence the size and speed of any payout and the costs deducted from it.

AI-generated analysis. Not financial advice.

Executive Accountability: Stephen Pakola, M.D. Named in REGENXBIO Securities Action

NEW YORK, March 12, 2026 /PRNewswire/ -- Stephen Pakola, M.D., REGENXBIO's Executive Vice President and Chief Medical Officer, is named as an individual defendant in a securities class action alleging that his repeated public assurances about the safety of RGX-111 gene therapy concealed material risks from investors. When the truth emerged on January 28, 2026, RGNX shares fell $2.40 per share, a decline of 17.8%, closing at $11.01.

Find out if you qualify to recover losses from RGNX or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.

Dr. Pakola's Role During the Class Period

As Chief Medical Officer, Dr. Pakola served as the primary spokesperson for REGENXBIO's clinical programs, including RGX-111, a gene therapy for severe Mucopolysaccharidosis Type I (MPS I). The complaint identifies Dr. Pakola as the executive who repeatedly communicated trial results to investors and the public across multiple press releases and earnings calls between February 2022 and November 2023.

What Dr. Pakola Allegedly Communicated to Investors

The action claims Dr. Pakola made a series of statements emphasizing that RGX-111 was "well-tolerated" with "no drug-related serious adverse events" and highlighting "encouraging CNS biomarker activity." These statements spanned multiple disclosure events:

• February 9, 2022: Announced "no drug-related serious adverse events" and "encouraging" biomarker and neurodevelopmental data from the Phase I/II trial
• February 28, 2023: Reiterated on the Q4 2022 earnings call that RGX-111 was "well tolerated, with no drug-related serious adverse events"
• May 3, 2023: Stated on the Q1 2023 earnings call that "RGX-111 was well tolerated in 8 patients" with an "encouraging CNS profile"
• November 8, 2023: Acknowledged de-prioritization of RGX-111, stating the company would seek "strategic alternatives"

Dr. Pakola's Certifications and Liability

As a senior officer with direct oversight of clinical programs, Dr. Pakola possessed the power and authority to control the contents of REGENXBIO's reports and press releases concerning RGX-111 trial data. The complaint contends he had access to non-public information about safety risks, including the potential for CNS neoplasm, yet continued to present an overwhelmingly positive picture of the therapy's safety profile.

Section 20(a) Context for Dr. Pakola

The securities action asserts that Dr. Pakola is liable as a controlling person under Section 20(a) of the Securities Exchange Act. As pleaded, he participated directly in the operation and management of the company's clinical affairs and was able to control the content of public disclosures about RGX-111's safety and efficacy.

"Individual officers who sign SEC certifications bear personal responsibility for the accuracy of corporate disclosures. When the executive responsible for clinical programs repeatedly assures investors that a therapy is well-tolerated while material safety risks allegedly remain undisclosed, accountability must follow." — Joseph E. Levi, Esq.

LEAD PLAINTIFF DEADLINE: April 14, 2026

Submit your claim to pursue recovery in the RGNX action or call (212) 363-7500.

Levi & Korsinsky, LLP, Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered for investors.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

jlevi@SueWallSt.com

Tel: (888) SueWallSt

Fax: (212) 363-7171

View original content:https://www.prnewswire.com/news-releases/stephen-pakola-oversaw-rgx-111-safety-claims-that-cost-rgnx-investors-millions-suewallst-302712044.html

SOURCE SueWallSt.com